Role of Pathology and Point of Care Testing in the Estimation of Fasting Blood Glucose Levels in Type 2 Diabetes Mellitus Patients
DOI:
https://doi.org/10.61919/jhrr.v4i1.448Keywords:
Type 2 Diabetes Mellitus, Fasting Blood Glucose, Hexokinase Method, End-Point Method, Glucometer, Point-of-Care TestingAbstract
Background: Diabetes mellitus (DM) is a global health concern with significant morbidity and mortality. Effective management of type 2 DM necessitates accurate monitoring of fasting blood glucose levels. Traditional laboratory methods, while accurate, are not always convenient for patients, leading to a growing interest in reliable point-of-care testing.
Objective: The aim of this study was to compare the accuracy of fasting blood glucose measurements between point-of-care testing using a glucometer and traditional laboratory methods (hexokinase and end-point) to determine the feasibility of home-based patient monitoring.
Methods: This comparative cross-sectional study included 150 type 2 DM patients from Farooq Hospital Westwood, Lahore. Participants underwent fasting blood glucose testing using three methods: the hexokinase method, the end-point method, and a glucometer (Accu-check instant S Meter). The Pearson correlation was employed to assess the linear relationship between the methods, while multivariate ANOVA was used to compare the means.
Results: The Pearson correlation coefficients indicated a strong positive correlation between the glucometer readings and both laboratory methods, with coefficients of 0.994 for hexokinase and 0.997 for the end-point method. The average fasting blood glucose levels measured were 128.43 mg/dL (±61.257) for hexokinase, 128.59 mg/dL (±61.110) for the end-point method, and slightly lower at 123.59 mg/dL (±58.920) for the glucometer.
Conclusion: The study concluded that glucometer readings are highly correlated with traditional laboratory methods, indicating that point-of-care testing can be a reliable alternative for patients to monitor fasting blood glucose levels at home.
Downloads
References
Gachoki JM. Comparative analysis of random blood glucose levels in serum, plasma and whole blood using glucose oxidase and hexokinase methods under spectrophotometric and electrochemical techniques: JKUAT-COHES; 2020.
Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A. The growing epidemic of diabetes mellitus. Current vascular pharmacology. 2020;18(2):104-9.
Kobiljonovna YS. FACTORS AFFECTING BLOOD GLUCOSE CONTROL. Новости образования: исследование в XXI веке. 2022;1(4):542-7.
Organization WH. Classification of diabetes mellitus. 2019.
Kumar R, Saha P, Kumar Y, Sahana S, Dubey A, Prakash O. A Review on Diabetes Mellitus: Type1 & Type2. World Journal of Pharmacy and Pharmaceutical Sciences. 2020;9(10):838-50.
Eizirik DL, Pasquali L, Cnop M. Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nature Reviews Endocrinology. 2020;16(7):349-62.
Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020;25(8):1987.
Bergman M, Abdul-Ghani M, DeFronzo RA, Manco M, Sesti G, Fiorentino TV, et al. Review of methods for detecting glycemic disorders. Diabetes research and clinical practice. 2020;165:108233.
Alqadi SF. Diabetes Mellitus and Its Influence on Oral Health. Diabetes, Metabolic Syndrome and Obesity. 2024:107-20.
Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From pre-diabetes to diabetes: diagnosis, treatments and translational research. Medicina. 2019;55(9):546.
Association AD. Standards of medical care in diabetes—2019 abridged for primary care providers. Clinical diabetes: a publication of the American Diabetes Association. 2019;37(1):11.
O’Malley EG, Reynolds CM, O’Kelly R, Killalea A, Sheehan SR, Turner MJ. A prospective evaluation of point-of-care measurements of maternal glucose for the diagnosis of gestational diabetes mellitus. Clinical Chemistry. 2020;66(2):316-23.
Ortiz-Martínez M, González-González M, Martagón AJ, Hlavinka V, Willson RC, Rito-Palomares M. Recent developments in biomarkers for diagnosis and screening of type 2 diabetes mellitus. Current Diabetes Reports. 2022;22(3):95-115.
Park H-D. Current status of clinical application of point-of-care testing. Archives of pathology & laboratory medicine. 2021;145(2):168-75.
VanMeter KC, Hubert RJ. Pathophysiology for the Health Professions E-Book: Elsevier Health Sciences; 2022.
Damhorst GL, Tyburski EA, Brand O, Martin GS, Lam WA. Diagnosis of acute serious illness: the role of point-of-care technologies. Current opinion in biomedical engineering. 2019;11:22-34.
Sing LT. An Uncommon but Important Cause of Bilateral Lower Limb Paresis or Paralysis. Emergency. 2024.
Kathmandu N. STANDARDIZATION OF VISIBLE KINETIC ASSAY FOR THE ESTIMATION OF PLASMA GLUCOSE BY GLUCOSE-OXIDASE AND PEROXIDASE METHOD.
Ayyanar K, Pichandi S, Janakiraman P. Evaluation of glucose oxidase and hexokinase methods. International Journal of Biotechnology and Biochemistry. 2018;14(1):51-8.
Zoungas S, Zhou Z, Owen AJ, Curtis AJ, Espinoza SE, Ernst ME, et al. Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial. The Lancet Diabetes & Endocrinology. 2024;12(2):98-106.
Khan AI, Pratumvinit B, Jacobs E, Kost GJ, Kary H, Balla J, et al. Point-of-care testing performed by healthcare professionals outside the hospital setting: consensus based recommendations from the IFCC Committee on Point-of-Care Testing (IFCC C-POCT). Clinical Chemistry and Laboratory Medicine (CCLM). 2023(0).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zainab Yousaf, Sania Ahmed, Muhammad Raza, Shamaila Rashid, Saba Qasim, Muhammad Touqeer Hanif
This work is licensed under a Creative Commons Attribution 4.0 International License.
